News

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drug candidates for CNS diseases, focusing on Alzheimer’s disease and pain, today announced that another scientific article has been published on the phase I clinical...

Research exploring low-grade systemic inflammation and its impact on the development and progression of neurodegenerative disease has increased. A particular research focus has been whether systemic inflammation arises only as a secondary effect of disease or is also...

Spinogenix, a clinical-stage biopharmaceutical company, announced that enrollment is open in Australia for its phase 2 clinical trial (NCT06427668) evaluating its investigational agent SPG302 as a treatment for patients with AD. SPG302, a once-a-day pill, has a unique...

Mechanism: Mitochondrial dysfunction is a key player in neurodegenerative diseases like Alzheimer's and Parkinson's. Preclinical research has focused on compounds that protect mitochondria from damage, reducing oxidative stress and inflammation in brain cells. One...

Mechanism: A new lithium-based compound, AL001, is being explored for its neuroprotective effects in dementia. Lithium has long been known for its benefits in mood stabilization but, at high doses, can cause side effects like kidney damage. This newer formulation uses...

Alzamend Neuro is partnering with Massachusetts General Hospital to conduct a Phase 2 clinical trial of AL001, an oral therapy being developed for dementia related to Alzheimer’s disease.

Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease.  Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University. In a press release published Jan. 24, Silo said...